A61K 51/1006
The antibody being against or targeting material from viruses
Official title: {the antibody being against or targeting material from viruses}
A61K51/1006 (The antibody being against or targeting material from viruses) appears on 12 US grants and 31 published applications in this corpus.
Search patents in A61K- Granted patents
- 12
- Published applications
- 31
- Assignees
- 21
- Inventors
- 84
- Latest grant
- 7 Mar 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 1 | 4 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 1 | 2 |
| 2009 | 1 | 1 |
| 2010 | 2 | 3 |
| 2011 | 0 | 0 |
| 2012 | 1 | 2 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 2 |
| 2019 | 0 | 0 |
| 2020 | 2 | 1 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 2 |
| 2024 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Multispecific antibodies that target HIV GP120 and CD37 Mar 2023US 11,597,759 B2Gilead Sciences, Inc.
- Multispecific antibodies that target HIV GP120 and CD35 Jan 2021US 10,882,907 B2Gilead Sciences, Inc.
- Multispecific antibodies that target HIV GP120 and CD317 Nov 2020US 10,836,825 B2Gilead Sciences, Inc.
- Stable IgG4 antibodies25 Aug 2020US 10,752,695 B2Genmab A/S
- Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin1 Aug 2017US 9,718,873 B2Children's Medical Center Corporation
- Fully Human Monoclonal Antibodies that Broadly Neutralize SARS-COV-218 Jul 2024US 2024/0239874 A2Oklahoma Medical Research Foundation
- Fully Human Monoclonal Antibodies that Broadly Neutralize SARS-COV-218 Jan 2024US 2024/0018217 A1
- Single-domain antibodies that bind sars-cov-219 Oct 2023US 2023/0331824 A1New York University
- Anti-oncolytic virus antigen antibodies and methods of using same26 Jan 2023US 2023/0027475 A1Admare Therapeutics Society
- Stable igg4 antibodies4 Mar 2021US 2021/0061919 A1Genmab A/S
Most cited
By later US patents
- Human neutralizing monoclonal antibodies to respiratory syncytial virus58US 5,762,905 AThe Scripps Research Institute · 1998
- Human neutralizing monoclonal antibodies to respiratory syncytial virus46US 6,685,942 B1The Scripps Research Institute · 2004
- Antibody compositions for the diagnosis and treatment of tumor34US 7,803,915 B2Genentech, Inc. · 2010
- Neutralizing monoclonal antibodies to respiratory syncytial virus23US 7,488,477 B2Intracel Resources LLC · 2009
- Neutralizing monoclonal antibodies to respiratory syncytial virus19US 8,221,759 B2Intracel Resources LLC · 2012